NEW YORK (GenomeWeb News) – Tecan has licensed molecular diagnostics intellectual property from Enigma Diagnostics that it will use to pursue development of an integrated diagnostics solution with another partner.
The Swiss lab technologies developer said today that the license covers IP that is used in Enigma's automated point-of-care molecular diagnostic system, the Enigma ML.
Financial terms of the license agreement were not released.
Tecan said that the license will enable it to expand its outside equipment manufacturer business, and that the integrated solution it hopes to develop with another potential partner will provide central labs with random sample access, complete automation, a "small footprint and a rapid time to result."
"The license provides us with the opportunity to approach a potential OEM partner with our concept of an integrated solution for molecular diagnostics that includes a unique instrument as well as enabling consumables," Tecan CEO Thomas Bachmann said in a statement.
The deal follows a five-year contract the companies signed last February under which Tecan is manufacturing the Enigma ML.